Neuroendocrine Tumors — CapTemY90 for Grade 2 NET Liver Metastases
Citation(s)
UPCC 04219 Phase 2 Study of Capecitabine-Temozolomide(CapTem) With Yttrium-90 Radioembolization in the Treatment of Patients With Unresectable Metastatic Grade 2 Neuroendocrine Tumors